January 12, 2018 / 1:51 PM / 7 months ago

BUZZ-Aradigm Corp: Ladenburg Thalmann cuts rating to 'neutral'

** Drug developer’s shares plunge 42.7 pct to $1.96 premarket - top pct loser among all U.S.-listed stocks

** Based on -ve Adcom vote on Thursday and resulting lack of clarity wrt regulatory pathway for Linhaliq, we’re lowering our rating to “neutral” from “buy”, removing PT - Ladenburg Thalmann

** An advisory committee to U.S. FDA voted 12-3 against co’s drug, Linhaliq, as a treatment for non-cystic fibrosis bronchiectasis with a bacterial infection

** FDA usually takes recommendations into account when making a drug approval, but is not obligated to follow them

** We expect it is likely Aradigm will receive a complete response letter for Linhaliq by the Jan 26 action date set by the U.S. FDA - Ladenburg Thalmann

** Company’s stock had risen more than four-fold in 2017 (Reporting by Akankshita Mukhopadhyay in Bengaluru)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below